EMA Authorised: Imlygic (talimogene laherparepvec) — Amgen Europe B.V.

View source ↗

Summary

The EMA authorised Imlygic (talimogene laherparepvec) for melanoma, with Amgen Europe B.V. as the marketing authorisation holder; decision dated 22 December 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Amgen Europe B.V.. Decision date: 22/12/2025